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Primary biliary cirrhosis (PBC) is a chronic immune-mediated cholestatic liver disease of unknown aetiology which aﬀects mostly
women in middle age. Familial PBC is when PBC aﬀects more than one member of the same family, and data suggest that ﬁrst-
degree relatives of PBC patients have an increased risk of developing the disease. Most often, these familial clusters involve mother-
daughter pairs, which is consistent with the female preponderance of the disease. These clusters provide evidence towards a genetic
basis underlying PBC. However, clusters of nonrelated individuals have also been reported, giving strength to an environmental
component. Twin studies have demonstrated a high concordance for PBC in monozygotic twins and a low concordance among
dizygotic twins. In conclusion, studies of PBC in families clearly demonstrate that genetic, epigenetic, and environmental factors
play a role in the development of the disease.
1.Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease characterised by an immune-mediated inﬂammatory
destruction of the small intrahepatic bile ducts, progressing
to ﬁbrosis, cirrhosis, and subsequent liver failure [1–3]. The
disease aﬀects mainly middle-aged women and is practically
absentinpaediatricage[1–3].Morethan90%ofthepatients
are women. The prevalence and incidence rates of the disease
vary between diﬀerent geographical areas. Studies from the
United Kingdom suggested not only that PBC is the most
frequent autoimmune liver disease (with the other two being
autoimmune hepatitis and primary sclerosing cholangitis)
but also that the disease aﬀects up to 1 in 800 women over
40 years of age [4]. Increasing trends of the incidence and
prevalenceofthediseasehavebeenreportedinUK,USA,and
Australia [4–6]. It remains elusive whether this increase is
trueorjustrepresentsearlierrecognitionofthediseasedueto
greater awareness and improved diagnostic tools [1–3]. PBC
aﬀects all ethnic groups but it appears to be more prevalent
in women of Caucasian origin. There is little information
about ethnic diﬀerences in PBC. A recent comprehensive
analysishasreporteddiﬀerencesoftheclinicalcharacteristics
betweenCaucasian,AfricanAmerican,andHispanicpatients
with PBC in the USA [7]. A signiﬁcant number of racial
minority patients were screened for the purposes of this
study. Peters et al. [7] reported that the establishment of
cirrhosis at clinical presentation is seen more frequently
in non-Caucasian compared to Caucasian PBC patients.
This diﬀerence could not be explained by demographic
or serological features alone. It remains unclear whether
increased awareness of PBC as a cause of chronic progressive
cholestatic disease among Caucasian compared to non-
Caucasian cases could explain the observed diﬀerences [7].
Of note, Hispanic and African American patients were of
similar age with the Caucasian ones. Migration studies
seem to indicate that migrants change their risk of PBC by
adapting to that of the population into which they move.2 Autoimmune Diseases
This has lead to the appreciation that environmental factors
play an important role in the development of the disease
[5, 8, 9].
The reason for the female predominance of PBC remains
unclear. Other autoimmune diseases with such strong female
preponderance are Sj¨ ogren’s syndrome and autoimmune
thyroiditis, two autoimmune diseases which frequently co-
occur with PBC [1–3]. There is no convincing reason which
can explain why these among other autoimmune diseases are
most frequently seen in cases with PBC.
Patients with PBC at diagnosis can be either asymp-
tomatic with normal biochemistry tests or asymptomatic
with abnormal biochemical blood tests, symptomatic, or
ﬁnally can have very advanced liver disease [1–3]. Pre-
sentation tends to be early and the diagnosis of PBC
most often is made when the patient is still asymptomatic
with an abnormal cholestatic liver biochemistry and an
immunological proﬁle compatible with the disease which
is discovered at a routine check [1–3]. The most frequent
presenting symptoms in patients with PBC are fatigue and
pruritus, and patients may be referred initially to dermatol-
ogists, endocrinologists, or neurologists [1–3]. The cause of
pruritus and fatigue remains unknown and does not always
correlate with the severity of the disease. Pruritus appears to
be worse amongst Hispanic and African Americans but the
reasons for that remain largely unknown [7]. Osteoporosis
may be the initial observation with no other symptoms or
signs of liver disease. In most cases, the disease advances in a
slow pace but symptoms of portal hypertension and hepatic
decompensation (jaundice, ascites, or variceal bleeding) can
develop several years after the original diagnosis [1–3].
The diagnosis of PBC is based on three widely accepted
criteria: biochemical signs of cholestasis, presence of disease-
speciﬁc autoantibodies, and diagnostic histological features
[1–3]. Histological features typical for PBC include destruc-
tion of biliary epithelial cells (BEC) and loss of small
bile ducts with portal inﬂammatory cell inﬁltration or less
frequently granulomas [1–3]. Early serological markers of
cholestasis include increased levels of alkaline phosphatase
and γG T .H i g hl e v e l so fI g Mm a yb ep r e s e n tb u tt h e
most prominent immunological feature of the disease is
the presence of diagnostically-relevant, high-titre antibodies
against mitochondrial (AMA) and nuclear (ANA) antigens
[1–3, 29–34]. While AMA do not appear to have clinical
signiﬁcance, disease-speciﬁc ANA can identify a subgroup
of PBC cases with more advanced disease [29, 30, 34–45].
A considerable proportion of patients may present with no
increase of IgM or may turn negative for autoantibodies,
with the latter ﬁnding largely depending on the sensitivity
of the tests used for their routine autoantibody detection
[32, 33, 46, 47].
Disease-speciﬁcAMAaredirectedagainstcomponentsof
the 2-oxo-acid dehydrogenase complexes (formerly known
as M2 antigen) and in particular the E2 subunits of
the pyruvate dehydrogenase complex (PDC), branched-
chain 2-oxoacid dehydrogenase complex (BCOADC), and 2-
oxoglutarate dehydrogenase complex (OGDC) [1, 29, 30, 32,
34]. More than 90% of AMA positive cases with PBC have
detectable anti-PDC-E2 antibodies [1, 29]. All PBC cases
reactive with PDC-E2 cross-react with the PDC E3 binding
protein (E3BP) [1, 29]. The E1α and E1β subunits of PDC
are subdominant targets [1, 29, 30, 32, 34]. AMA can be of
the IgG, IgA, and IgM isotypes. High titre AMA-M2 of class
IgG are found in up to 95% of patients but in less than 2%
of pathological and healthy controls [1, 29]. Nevertheless,
various studies reported that the presence of AMA is much
higher than the prevalence of PBC in the general population,
indicating that AMA may precede the symptomatic onset of
the disease [48]. Studies investigating the natural history of
PBC have demonstrated that AMA-positive, asymptomatic
patients often have histological features diagnostic of, or
compatible with PBC [48–51]. Taken together, these ﬁndings
indicate that AMA is a very powerful predictor of future
developmentofPBC.Assuch,thequestionhasbeenraisedas
to whether potential screening programmes for AMA should
be adopted, especially for female relatives of PBC patients
[34, 52]. To date, no general consensus has been met.
As AMA are not the only disease-speciﬁc autoantibodies,
there is an ongoing discussion as to whether diagnostic test-
ing needs to incorporate assays for PBC-speciﬁc ANA [34].
Two PBC-speciﬁc ANA IFL patterns have been identiﬁed:
autoantibodies giving the “multiple nuclear dots” pattern
mainly target the nuclear body sp100 and PML proteins, and
those giving the “nuclear membrane” (rim) recognise gp210,
nup62 and other nuclear membrane proteins [30, 31, 34,
53]. Both ANA types can be found in approximately 30%
of PBC patients and show a signiﬁcant disease speciﬁcity
[30, 31, 53]. These disease-speciﬁc patterns can be present in
AMA-positive and AMA-negative asymptomatic individuals
and also in family members of PBC patients. When these
antibodies are present at diagnosis, they seem to be able
to identify individuals who will develop advanced disease
faster than those seronegative for these autoantibodies [54].
Antibodies against centromere are mainly present in PBC
cases with concurrent CREST syndrome and their presence
is associated with a more advanced disease [40, 55].
The mechanisms responsible for the induction of PBC-
speciﬁc AMA and ANA responses are poorly understood
[29, 56–61]. In vitro studies implicate antigen-speciﬁc B-,
CD4, CD8 T-lymphocyte responses in the induction and/or
maintenance of autoaggressive pathology [51, 57, 58, 62–
65]. Animal models resembling PBC suggest that both arms
of innate and adaptive immunity contribute to the disease
development [57, 66, 67].
As for other autoimmune diseases, genetic, epigenetic,
environmental, and infectious factors have been consid-
ered important for the development of the disease or
its progression from early stages to more advanced, life-
threatening biliary epithelial cell destruction [23–25, 57, 58,
65–79]. Familial studies have provided evidence towards
both genetic and environmental causes [26, 27, 68]. Recent
genomic studies have provided data which correlates with
the increased incidence of PBC in families, as well as the
increased incidence of autoimmune disease in both PBC
patients and their relatives [23–25]. In order to diﬀerentiate
between environment and genes (or a combination of
the two), twin studies have been considered essential as
monozygotic twins would share the same genetic materialAutoimmune Diseases 3
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Figure 1: Understanding the pathogenesis of the disease also stems
from studies of familial primary biliary cirrhosis (PBC). Clues as to
the pathogenesis of the disease are provided by population studies
involving a large number of families of aﬀected individuals and case
reports (see also Table 1). These studies support the notion that the
pathogenesis of the disease is complex, and that genes, epigenetic
factors, and environment are mostly likely involved in concert
rather than in isolation. The relative contribution of each of those
factors is largely unknown and may vary among individuals and
clusters. Their participation may be important for the induction
of the immunopathological processes leading to PBC development,
butmayalsobeimportantfortheprogressionofthediseasetowards
a favourable slow pace or an unwanted progressive deterioration.
and therefore have a high disease concordance. Likewise,
dizygotic twins would share environmental factors, but diﬀer
genetically (Figure 1).
2. Overview of Primary Biliary
CirrhosisinFamilies
Like many autoimmune diseases, PBC infers an increased
risk of developing the disease in relatives of an aﬀected
individual. Some of the major ﬁndings of the familial studies
inPBCaresummarisedinTables1and2.BachandSchaﬀner
[10] at Mount Sinai Hospital in New York conducted a
retrospective review to determine the prevalence of PBC
within family members of PBC patients. Out of a total of
405 patients with PBC, 26 also had at least one ﬁrst-degree
relative (FDR) who also had PBC or liver disease that was
unspeciﬁed but suggestive of PBC [10]. The prevalence of
PBC was calculated to be 4.3% in families with at least
one relative with PBC, or 14.9% when taking into account
those with undiagnosed liver disease with some features
Table 1: Some clues for the aetiopathogenesis of primary biliary
cirrhosis (PBC) are provided by family studies.
References
Genes
(a) High incidence of mother-daughter pairs, and
sister-sister pairs [10–19]
(b) Increased incidence in PBC rates in families of
PBC patients [10–14]
(c) Similar AMA reactivity proﬁles shared among
aﬀected relatives [12]
(d) HLA DR8, the allele associated with
susceptibility to PBC is found in familial cases [12, 20]
(e) Increased incidence of autoimmunity in PBC
patients and their families [13, 21, 22]
(f) Identiﬁcation of non-HLA genes with increased
incidence among PBC patients (e.g., STAT4, CTLA4) [23–25]
(g) Increased concordance among monozygotic but
not dizygotic twins [26]
Environment
(a) Husband and wife with PBC (also shared same
environment in childhood) [27]
(b) Three unrelated females who shared same work
environment developed PBC [27]
(c) Women and daughter-in-law developed PBC [27]
Combined/Undiﬀerentiated Genes and Environment
(a) Two unrelated women sharing same environment
as well as HLA and AMA patterns developed PBC [20]
(b) Five of ten siblings in the same family developed
PBC, two were asymptomatic but AMA positive,
three AMA negative and asymptomatic
[27]
(c) Mother-daughter-close family friend developed
PBC [28]
A thorough list of studies reporting familial PBC in support of the role
of genes and/or the environment in the pathogenesis of the disease is
discussed in the main text, with the references in this table being a small
representation.
compatible with PBC [10]. These ﬁgures are signiﬁcantly
higher than the general population, where PBC rates are
between 0.7 and 7.5 cases per 100,000 [10]. This was also
the case cited by Floreani et al. [11], who noted similar
rates of PBC in families in Italy (3.8%), and Tsuji et al.
[12] cited a familial PBC prevalence of 5.1%. Tsuji et al.
[12] also noted a higher (944 times) PBC rate among
families in Hiroshima, compared to 210 times higher in
the remainder of Japan, when compared to the general
population. Gershwin et al. [21] and Corpechot et al. [13]
reportedsimilarFDRincidenceratesofPBCat5.9%and4%,
respectively, which is consistent with other studies placing
the familial incidence of PBC among FDR of PBC patients at
approximately 4–6% [10–12, 14]. These rates are higher than
those reported in an early study by Brind et al. [15]f r o m
King’s College Hospital, which reports a familial incidence
of 1.33%. Jones et al. [14] notes a familial prevalence of
PBC of 6.4%, based on 157 patients with PBC, 10 of which
had family histories of PBC (8 of the 10 were FDR). That
study provided a clearer view of which relatives are most4 Autoimmune Diseases
Table 2: Main features of familial Primary Biliary Cirrhosis (PBC).
Prevalence of PBC is increased in families with members
aﬀected by PBC. Prevalence rates range from 4 to 6%
Most aﬀected members of the same family are females, with the
most common pairing being in mother-daughters or
sister-sisters
PBC rarely aﬀects males, with few conﬁrmed case reports of
males relatives being aﬀected
Increased incidence of autoimmune disease in families of PBC
patients, most commonly Sicca syndrome and autoimmune
thyroid disease
Diagnosis of a second or more family member often occurs
within a short time interval of the initial case. This may be due
to early screening for cholestasis or AMA initiated by the initial
diagnosis
Concordance rates among monozygotic twins are among the
highest of the autoimmune diseases
PBC in extended families (i.e., family members not related
genetically) is rare, but has been reported mainly in husband
and wife pairs, but at least one reports PBC in a female and her
mother-in-law
Studies in support of the main ﬁndings in families of patients with PBC are
discussed in the main text; AMA: antimitochondrial antibody.
at risk of developing PBC [14]. In general, FDR had a
0.72% prevalence of developing PBC, whereas siblings of
PBC patients had a prevalence of 0.4% [14]. Oﬀspring
of PBC patients had a much higher prevalence at 1.2%,
but daughters speciﬁcally had a 2.3% prevalence, which is
consistent with clinical observation and case reports where
mothers and daughters had the highest concordance of PBC
[15], followed by sisters [21].
Numerous studies on the demographics and risk factors
of PBC have demonstrated common features among larger
cohorts of PBC patients and their families. A well-performed
studybyGershwinetal.[21]demonstratedthatautoimmune
d i s e a s e sw e r eac o m m o nf e a t u r ei nP B C ,a si tw a sp r e s e n t
in 32% of PBC patients compared to 13% of controls. An
increased incidence of autoimmune disease was also found
in a study by Prince et al. [22], as well as in the study on PBC
demographicsbyCorpechot andcoworkers[13].TheFrench
study by Corpechot et al. [13] indicates that autoimmune
conditions were not only common among PBC patients, but
also more common among their FDR. Bach and Schaﬀner
also noted a higher incidence of autoimmune disease among
FDR of PBC patients (approximately 71%) [10].
3.PrimaryBiliaryCirrhosisinMale Relatives
Although rare in males, some cases of PBC occurring among
male relatives have been reported. Early case reports have
included PBC in a set of brothers [80]; however, it is
uncertain whether this was indeed a case of familial PBC,
as the diagnostic robustness in these early case reports is
questionable. Tanaka et al. [81] cite two case studies of
PBC occurring in brothers (one set in England, the other
in France); however, the AMA status and clinical course
of the two pairs remains obscure. Lazaridis et al. [16]
report PBC occurring in brothers of PBC patients, but it
has not been indicated whether the proband case was male
or female. Of interest, the same investigators also report
PBC cases occurring in father-daughter pairs, but none
in father-son pairs [16]. Tanaka and coworkers also cite
several father-daughter pairs and two brother-sister pairs,
but again, clinical follow-up of these cases has not occurred,
prohibiting a view of the disease progression and behaviour
[81]. Lazaridis et al. found a PBC rate of 7.8% among
brothers and 3.7% in fathers [16].
4.PrimaryBiliaryCirrhosisin
Mothers and Daughters
Asmentioned,themostfrequenttypeofPBCclustersinfam-
ilies is reported in mother-daughter pairs [14, 15], followed
by sisters [21] or mother-sister-daughter [17]. This is not
surprising, as PBC is predominantly found in middle-aged
females. Jaup and Zettergren [18] have reported a cluster
of PBC in as many as four of six sisters. Abu-Mouch et al.
[27] examined a cluster of PBC in a family in great detail.
This cluster consisted of 10 siblings (8 sisters and 2 brothers)
of Palestinian origin living in the same area. Five sisters
presented with PBC within 10 years of each other and had
high titre AMA with similar reactivity patterns and clinical
stage [27]. Of the remaining three sisters, two tested weakly
positive for AMA, and one had neither positive AMA nor
PBC [27]. The two brothers and the mother were also neg-
ative for AMA and did not have ﬁndings suggestive of PBC.
Prevalence rates of PBC are increased among sisters and
daughters of PBC patients. The study by Lazaridis et al. [16]
found a 20.7% prevalence among sisters of PBC patients.
In a report by Fagan et al., a mother-daughter pair, among
the ﬁrst-degree relatives, only the mother and daughter
shared both genetic relations and a common environment,
having been separated for only one year [17]. Environmental
inﬂuences in the disease progression were noted due to the
short period of time between the diagnosis of PBC in the
two women [17]. Other early case reports also indicated a
m o t h e rd a u g h t e rp a i rb e i n ga ﬀected by PBC with quite a
distinct clinical course amongst the aﬀected individuals of
the disease [19]. Douglas and Finlayson [28] also report PBC
in a mother daughter pair, as well as in a close family friend.
The daughter was the ﬁrst of the three to present with PBC
and was nursed through her terminal illness by the mother
and family friend [28]. The mother and friend presented
with PBC within 21 months of the daughter’s death [28].
The short period of time between the diagnoses in the
three women also seemed to indicate that these women were
exposed for the same duration to a common environmental
factorwhichtriggeredPBC.Autoantibodytestinginthethree
women showed the presence of AMA [28]. Autoantibody
testing of FDR of the mother-daughter pair revealed the
presence of autoantibodies in several relatives, including
AMA; however, none of these individuals were reported to
have PBC [28]. It is possible that these individuals would
have developed PBC or abnormal liver biochemistry, but no
lengthy follow-up occurred.Autoimmune Diseases 5
It is usually the case that at the time of diagnosis of PBC
in a middle age woman, screening for AMA and a cholestatic
form of abnormal liver function tests are also arranged for
her siblings (mainly sisters) and mother. It is not unusual
for some of those to turn positive for AMA with or without
abnormal liver biochemistry. As mentioned, the mother
daughter type of familial PBC is not the only one. Various
other combinations have been noted but in most of those the
diagnosis of PBC is diﬃcult to prove and can be challenged
[82].Insomeofthese,liverbiopsieshavenotbeenperformed
or their ﬁndings are not entirely conﬁrmatory of the disease,
while in others the diagnosis of the disease is largely based
on the presence of the antibodies and some nonspeciﬁc
symptoms. No one has followed these asymptomatic AMA
positive cases for long, but it is likely that a proportion of the
AMA-positive asymptomatic relatives will develop abnormal
liver biochemistry, and/or progress to PBC [48]. Due to
the potential of a changing clinical course in asymptomatic
patients, it is recommended that female FDR of PBC patients
undergo immunological and liver function proﬁling, with a
lengthy course of follow-up.
A higher frequency of monosomy of the X chromosome
(a major X chromosome defect) in peripheral leukocytes
of female PBC patients has been noted by Invernizzi and
coworkers [75, 83]. This characteristic has been found in
other autoimmune diseases with a high female preponder-
ance such as systemic sclerosis and autoimmune thyroid
disease. Genes important for the homeostasis of sex hor-
mones and the maintenance of immunological tolerance are
locatedontheXchromosome.Forexample,theCD40ligand
(CD40L) is an X-linked gene responsible for the X-linked
immunodeﬁciency associated with increased serum levels of
immunoglobulins M; IgM levels are typically increased in
the great majority of cases with PBC. It could be argued
that X chromosome related dysregulation may explain the
female preponderance of PBC, and that the physiological
inactivation of the X chromosome could account for the
prevalence of PBC occurring peri-menopause [67, 83, 84].
This could also explain why systemic sclerosis and autoim-
mune thyroiditis are frequently seen in patients with PBC.
The exact role of X monosomy in PBC may be more
complex. Several scenarios have been proposed to explain
how monosomy X is involved in the pathogenesis of PBC
[57, 75, 83–85]. It has been argued [84] that “PBC could
arise from a polygenic model with an X-linked major
locus of susceptibility with genes escaping inactivation being
involved; the female susceptibility might therefore as well
derive from genes mapping on the Y chromosome [84].
The second scenario suggests that PBC susceptibility might
arise from a multigenic complex inheritance model in which
speciﬁc Y-linked genes are protective. Conversely, X-linked
genes would interact with other genes and be involved via a
dose-dependent eﬀect” [84]. Subsequent studies supported
the notion that enhanced X monosomy in peripheral blood
mononuclear cells from patients with PBC preferentially
involves only one parentally derived chromosome, and is not
secondary to a constitutive nonrandom pattern of X chro-
mosome inactivation [85]. The existence of X-chromosome
inactivationinfemalesoﬀersapotentialmechanismwhereby
X-linkedself-antigensmayescapepresentationinthethymus
or in other peripheral sites that are involved in tolerance
induction. The fact that X-chromosome monosomy in PBC
is particularly evident in peripheral B lymphocytes and
T lymphocytes in PBC patients’ cell subpopulation which
are important for the development of PBC, strengthens
this notion. Thus, predisposed females may be in a state
where under speciﬁc circumstances, they can express X-
linked autoantigens in the periphery to which they have
been ineﬃciently tolerised. We need to identify these genes
and dissect their exact relation with PBC. As monosomy
X is not the characteristic feature of the peripheral blood
mononuclear cells from all patients with PBC, it can be
argued that inactivation of chromosome X cannot explain a
priori the induction of PBC.
5. Twin Studies
Few studies or case reports exist that speciﬁcally examine
PBC in twins. Chohan reports a set of twin sisters with
PBC, but genetic, environmental, and other relevant medical
histories are lacking in this report [86]. Selmi et al. [26]
performed a study consisting of 8 sets each of monozygotic
and dizygotic pairs. Four pairs were females, and the
remaining four were male-female. The concordance rate of
PBC among the monozygotic pairs was 0.63 (5 of 8 pairs
were concordant for PBC) [86]. It could be argued that as
the concordance was not 1.0, genetic factors do not play a
role in PBC pathogenesis. However, a concordance of 0.63
is one of the highest among the autoimmune diseases. As
well,itispossiblethattheasymptomatictwinsdideventually
develop PBC over time. All aﬀected individuals were female,
with the majority (four of ﬁve sets) being of white ethnicity,
and one set being Asian [26]. The age of PBC presentation
was between 33 and 60 years [26]. Most of the sets presented
at the same age, or within two years of each other. Most
twin sets had the same presenting symptoms of pruritus,
fatigue, or a combination of the two. In one pair (set 2),
one twin presented with liver failure and required liver
transplantation, whereas the other twin had no presenting
symptoms over a 13-year follow-up [26].
Among the monozygotic twin sets, three were discordant
for PBC. Two of them were positive for AMA with no
abnormal liver function tests. Most of the twin sets had Sicca
symptomatology, which is present in the majority of PBC
patients. However, set 4 had autoimmune hypothyroidism,
and one twin in set 1 had autoimmune hepatitis [26]. The
high incidence of other autoimmune diseases indicates a
possible propensity to autoimmunity in genetically suscep-
tible individuals. The diﬀering histological grades, dissimilar
clinical course, and variable autoimmunity do not favour a
clear cut genetic cause. Indeed, there was great variability
among the sets of twins. Twins in set 4 had the same age
of presentation as well as presenting symptoms, histological
grades, and autoimmune hypothyroid [26]. Set 2 had few
similarities, and drastically diﬀerent clinical courses and
histological grades. Selmi et al. [26] indicates that these
variances may be due to an interplay between genes and
environment, as well as possible diﬀerences on the epigenetic6 Autoimmune Diseases
level. Although their study was unable to indicate speciﬁc
environmental triggers, other authors have suggested envi-
ronmental toxins, xenobiotics, and microbial/self molecular
mimicry [56–60, 65, 66, 70, 71, 73–75, 77, 78, 87–102].
6.PBC inthe ExtendedFamily
Twin studies have provided evidence towards both genetic
and environmental inﬂuences in the pathogenesis of PBC.
Extended families provide some evidence towards environ-
mental inﬂuences, as individuals such as husbands and wives
share a common environment, but usually no genetic sim-
ilarities. The report by Abu-Mouch has provided examples
of such cases [27]. One cluster was a husband and wife
with PBC, who grew up in the same neighbourhood in
Michigan, and who’s only reported risk factors were cigarette
smoke, and recurrent UTI’s—a well-documented risk factor
for PBC—in the female. The husband was ﬁve years younger
and developed the disease ﬁve years after his wife had
been diagnosed with PBC, but he had histologically more
advanced disease compared to his wife [27]. The lack of
husband/wife PBC pairs in the literature clearly indicates
the extreme rarity of conjugal PBC. Another cluster was a
family where PBC was present in two genetically unrelated
individuals (grandmother and her daughter-in-law) [27].
The daughter and grand-daughter of the grandmother were
AMA positive but asymptomatic, and the daughter-in-law
was from Korea (where there is a low PBC rate). The
grandmother and her daughter-in-law shared the same
house for 2 years and then lived in the same neighbourhood
for 30 years [27]. Whether or not environment played a large
role in that cluster, or whether those individuals had genetic
susceptibility to PBC and the development of the disease was
purely by chance, remains unknown.
7.GeneticandEpigenetic Studies
A point of interest noted above is that which relates to
the increased prevalence of autoimmune diseases unrelated
to PBC or other autoimmune diseases. The exact cause of
this may relate to genes conferring susceptibility to various
autoimmune diseases. For example, Hemminki et al. [103]
indicate relatively weak but signiﬁcant associations between
STAT4 and CTLA4 loci with RA and SLE in the case of
STAT4, and to RA and other autoimmune disease in the
case of CTLA4. Hirschﬁeld et al. [25] set out to identify
genetic loci conferring a risk for PBC, by carrying out a
genome-wide association analysis of 536 PBC patients and
1536 controls from Canada and the USA. A signiﬁcant
association between PBC and 13 loci across the HLA class
II region, with HLA DQB1 having the strongest association
[25]. Associations were also made in non-HLA genes, with
two single-nucleotide polymorphisms (SNPs) at the IL12A
loci, and one SNP at the IL12RB2 locus. Associations with
SNPs at the STAT4 and CTLA4 loci were also found, but to
a lesser degree [25]. Liu et al. [23] had similar ﬁndings in
regardstoIL12AandIL12RBinanItaliancohort,inaddition
to associations with several HLA regions (namely, DRB1,
DQA1,DQB1,DQA2),IRF5,SPIB,andtheIKZF3-ORMDL3
of chromosome 17q12-21. These ﬁndings are interesting,
as STAT4 plays a role in IL12 signalling, and its role in
PBC may be signiﬁcant due to its association with other
autoimmune diseases such as RA and SLE [23]. Based on
theseﬁndings,itwouldbeexpectedthatPBCwouldco-occur
frequently with RA or SLE, and vice versa. However, PBC
more often co-occurs with Sicca syndrome and autoimmune
thyroiditis,andwewouldexpectthatthesediseasesalsoshare
an association with STAT4. Hirschﬁeld et al. [24] have also
demonstrated an association between PBC and genes at the
IRF5-TNPO3 locus, at chromosome 17q12-21, and at loci
MMEL1 in a cohort of PBC patients of European descent.
These ﬁndings were of great interest, as IRF5-TNPO3 has
been previously associated with other autoimmune diseases,
n a m e l y ,S L E ,s y s t e m i cs c l e r o s i s ,a n dS j¨ ogrens syndrome [24].
Hirschﬁeld’s study has also provided fascinating data in
regards to a potential genetic characterisation of individuals
with ANA positivity [24]. Within the main cohort, 462
PBC individuals with ANA positivity were evaluated as a
subset, and an association was found with HLA-DPB1 in
those with anti-Sp100 [24]. No association was found in
those with ANA positivity with anti-gp210 [24]. Although
this cohort was relatively small, the ﬁndings indicate a
potential correlation between HLA type and ANA status,
which warrants further study due to its potential prognostic
value.
Several HLA haplotypes have been reported within
families, but only HLA-DR8 has been reported to be found
consistently. Tsuji et al. [12] analysed 18 patients from
8 families with more than one FDR with PBC. Aﬀected
members among the same family shared HLA haplotypes,
but these patterns were not often shared among the 8
families, with the exception of HLA-DR8, which was found
in 29.4% of patients [12]. HLA DR8 has been considered
a risk factor for developing PBC, especially in Caucasian
populations [104]. Von Mach [20] notes similar antigenic
and HLA patterns in a report of two women who were not
related, but shared a common environment (they shared a
deskatschooluntiltheageof10).Bothwomenhada25-year
history of liver enzyme abnormalities and were diagnosed
with PBC in a short time interval between each other [20].
Both were AMA positive, with a strong reaction to PDC-E2
[20]. Both women shared HLA haplotypes A2, B51, DR4,
DR53, and, not surprisingly, DR8 [20, 104].
The diﬀering concordance rates among monozygotic
twins noted above may be attributed to epigenetic causes.
Disconcordance due to epigenetic factors among identical
twins has been observed in other conditions. In Beckwith-
Wiedmann syndrome, diﬀerences in imprinting of the
KCNQ10T1 gene have been implicated in the discordance
rates among twins with this condition. As well, methy-
lation pattern diﬀerences among twins with Silver-Russell
syndrome have also been demonstrated to account for
discordance among monozygotic twins. A recent study by
Mitchell et al. [105] reports epigenetic diﬀerences found in
discordant monozygotic twins with PBC. It has been found
that there is an increased X chromosome monosomy rate
in the peripheral lymphocytes of female patients with PBCAutoimmune Diseases 7
[75, 83, 105]. Most genes on the inactivated X chromosome
are silenced via promoter methylation, but a small propor-
tion of these may escape this process. Mitchell et al. [105]
obtained mRNA and DNA from peripheral blood from four
setsofmonozygotictwinswhowerediscordantforPBC.Two
genes, CLIC2 and PIN4, were consistently downregulated
in the twin with PBC [105]. This was not found in the
healthy twin or in control subjects. In both genes, it was
found that methylation was partial or variable and did
not predict transcript levels or X inactivation status [105].
CLIC2 encodes for an intracellular calcium channel and
regulates calcium homeostasis via the ryanodine receptors.
Abnormalities in intracellular calcium may lead to cellular
and tissue damage which, if occurring in the liver, may
lead to liver disease [105]. PIN4 is involved in mitoses,
cell proliferation, chromatin remodelling, and epigenetic
mechanisms involving ATP-dependent changes to histone
modiﬁcations [105]. PIN4 dysregulation could therefore
potentially lead to an alteration in the function of genes
which may be protective or pathogenic [105]. What role
these genes play in the pathogenesis of PBC and its variable
concordance among identical twins remain to be seen [67,
78].Epigeneticstudiesofrelatedandnonrelated(butsharing
a common environment) individuals with PBC also warrant
further study.
8.FutureProspects
Areas for future work include elucidating those environmen-
tal factors which are associated with PBC, and determining
the mechanism by which they induce disease. This is not,
however, an easy task. Most of the work done in the
search for environmental triggers rely on animal models,
addressing one compound at the time. Worryingly enough,
the most frequent tool that epidemiologists can use in order
to identify multiple environmental exposures linked to a
speciﬁc autoimmune disease (PBC in our case) is that of
questionnaires or access to data extracted from medical
records. This is in sharp contrast to the information of
large genome-wide association studies which more or less
provide measurable information for the totality of genes as
risk factors. Ideally, one would like to be able to accurately
measure simultaneously the totality of exposures received by
a person during life in order to investigate the environmental
causes of chronic diseases. These factors may also include the
chemical by-products within the body, which are produced
by inﬂammation, oxidative stress, gut ﬂora and infection,
as well as through a bio-psycho-social axis. The collation of
all these external and internal environmental factors from
conception onwards has been named as the “exposome”
[106–108]. It has been suggested that several measurements
on exposomal factors may be done through multiple blood
samples over several years, which would characterise changes
in environment [108]. In the case of familial PBC, multiple
samples of at risk individuals may shed some light on which
factors are critical for the development or progression of
PBC. The exposome may very well turn out to be the envi-
ronmental equivalent of the genome-wide association study,
which would allow a quantitative measure of the eﬀects of a
broad range of environmental triggers and carefully selected
infectious agents in the pathogenesis of disease [109].
9. Conclusions
In conclusion, studies of patients with PBC demonstrate a
higher prevalence of PBC among families, which is too high
and too frequent to be attributed to chance alone. As well,
several studies have shown that unrelated individuals who
shared a common environment also had a higher incidence
of PBC. As these reports are rare, it is diﬃcult to speculate
as to whether these are attributable to chance, or a common
environmental trigger. Nevertheless, each of these studies
has a story to tell. Familial PBC raises the question as to
whether genetic or environmental factors are at the cause of
thedisease,andtwinstudiesraisethepossibilityofepigenetic
phenomena also. It most likely that genetic, epigenetic, and
environmental factors work in unison, with varying degrees
of inﬂuence on the disease progression within the individual
as well as their families. Despite our advances in knowledge
surrounding these individual factors, it will likely be some
time before the causes of PBC and their interaction with one
another are well deﬁned.
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